These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21232670)

  • 1. Vernakalant: additional evidence for safety and efficacy for new onset atrial fibrillation.
    Lindsay BD
    J Am Coll Cardiol; 2011 Jan; 57(3):322-3. PubMed ID: 21232670
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
    Guerra F; Matassini MV; Scappini L; Urbinati A; Capucci A
    Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1067-75. PubMed ID: 25096598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.
    Vizzardi E; Salghetti F; Bonadei I; Gelsomino S; Lorusso R; D'Aloia A; Curnis A
    Cardiovasc Ther; 2013 Oct; 31(5):e55-62. PubMed ID: 23398692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
    Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1:1 atrial flutter after vernakalant administration for atrial fibrillation cardioversion.
    de Riva-Silva M; Montero-Cabezas JM; Salgado-Aranda R; López-Gil M; Fontenla-Cerezuela A; Arribas-Ynsaurriaga F
    Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1062-4. PubMed ID: 22727797
    [No Abstract]   [Full Text] [Related]  

  • 6. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
    Hinneburg I
    Med Monatsschr Pharm; 2011 May; 34(5):154-8. PubMed ID: 21644373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
    Conde D
    Int J Cardiol; 2013 Oct; 169(2):95-6. PubMed ID: 24071384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vernakalant versus electrical cardioversion in recent-onset atrial fibrillation.
    Conde D; Lalor N; Rodriguez L; Elissamburu P; Marcelo T
    Int J Cardiol; 2013 Oct; 168(4):4431-2. PubMed ID: 23890913
    [No Abstract]   [Full Text] [Related]  

  • 9. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
    Billman GE
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG; Roos JS; Kavanagh KM; Dickinson G
    Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vernakalant: pharmacology electrophysiology, safety and efficacy.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
    Drugs Today (Barc); 2008 May; 44(5):325-9. PubMed ID: 18548135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
    Beatch GN; Bhirangi K; Juul-Moller S; Rustige J
    J Cardiovasc Pharmacol; 2017 Feb; 69(2):86-92. PubMed ID: 27828791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
    Camm AJ; Capucci A; Hohnloser SH; Torp-Pedersen C; Van Gelder IC; Mangal B; Beatch G;
    J Am Coll Cardiol; 2011 Jan; 57(3):313-21. PubMed ID: 21232669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vernakalant in the management of atrial fibrillation.
    Cheng JW
    Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents for the acute conversion of atrial fibrillation: focus on vernakalant.
    Cialdella P; Pedicino D; Santangeli P
    Recent Pat Cardiovasc Drug Discov; 2011 Jan; 6(1):1-8. PubMed ID: 21235460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
    Stoneman P; Gilligan P; Mahon P; Sheahan R
    Ir J Med Sci; 2017 Nov; 186(4):903-908. PubMed ID: 28168639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vernakalant. Too dangerous in atrial fibrillation.
    Prescrire Int; 2012 May; 21(127):119-22. PubMed ID: 22827000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New concepts in the therapy of atrial fibrillation].
    Shin DI; Eckardt L
    Dtsch Med Wochenschr; 2011 Aug; 136(31-32):1587-90. PubMed ID: 21809248
    [No Abstract]   [Full Text] [Related]  

  • 19. Flecainide or propafenone vs. vernakalant for conversion of recent-onset atrial fibrillation.
    Conde D; Costabel JP; Aragon M; Caro M; Ferro A; Klein A; Trivi M; Giniger A
    Can J Cardiol; 2013 Oct; 29(10):1330.e13. PubMed ID: 23465347
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness and safety of vernakalant vs flecainide for cardioversion of atrial fibrillation in the emergency department: the VERITA study.
    Dominijanni G; Caballero-Bermejo AF; Martín Jiménez ML; Calpe Delgado P; Rodríguez-Miranda B; Ruiz-Antorán B
    Emergencias; 2024 Jun; 36(3):239-240. PubMed ID: 38819000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.